A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

NCT07018544 · Enrolling by invitation

Last updated 2026-05-28

This study is observing the safety of Wegovy® (semaglutide) in adults with obesity or overweight in real-world clinical settings in Korea.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 840 people Planned (estimated).

Who can join Ages 19+ · all sexes

Timeline Started 2024-11 · est. completion 2027-02

Where 8 sites · South Korea

What this study is testing ClinicalTrials.gov NCT07018544 ↗

Description as written by the study sponsor.

This study is conducted to investigate the safety and effectiveness of semaglutide in participants with obesity and overweight in routine clinical practice. Participants will get semaglutide as prescribed by a doctor. This study will last for about 4 years and participants will participate in the study for approximately 26 weeks.

Treatments tested

semaglutide also known as Wegovy Other

Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Main thing measured	Number (incidence) of AEs
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity and Overweight
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07018544 ↗